Barr's Generic Lanthanum Carbonate Receives Approval in U.S.
When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month's supply.
Barr Labs` Generic Clozapine Receives Approval In US
The Food and Drug Administration (FDA or Agency) is withdrawing approval ofn68 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of thenapplications notified the Agency in writing that the drug products were no longer marketed andnrequested that the approval of the applications be withdrawn.
The Food and Drug Administration (FDA) is withdrawing approval of 54nabbreviated new drug applications (ANDAs) from two applicants. The holders of thenapplications notified the Agency in writing that the drug products were no longer marketed andnrequested that the approval of the applications be withdrawn.
Newark, Calif.-based Depomed (DEPO) has been in an ongoing battle with Jeffrey Smith, managing member of hedge fund Starboard Value LP, and appears to have lost.
The case, which began in 2000 in California state court, centers on a series of settlements in the late 1990s under which Bayer allegedly paid Barr Pharmaceuticals, since bought by Teva, $398 million not to market Cipro's generic version. Bayer had earlier sued Barr claiming that generic Cipro would infringe a Bayer patent. reut.rs/2jkzNtL
U.S. Supreme Court declines to hear FTC, Boehringer document fight
Last week, in Eli Lilly and Company v. Teva Parenteral Medicines, Inc., Judge Tanya Walton Pratt of the U.S. District Court for the Southern District of Indiana determined that Eli Lilly and Company had shown by a preponderance of the evidence that U.S. Patent No. 7,772,209, owned by Lilly, would be infringed by the ANDA products for which Defendants Teva Parenteral Medicines, Inc.; Teva Pharmaceuticals USA, Inc.; APP Pharmaceuticals, LLC; Barr Laboratories, Inc.; and Pliva Hrvatska D.O.O. sought approval to market (opinion).
G.D. Searle LLC v. Lupin Pharmaceuticals, Inc. (Fed. Cir. 2015)